Logo image of ARCH.CA

ARCH BIOPARTNERS INC (ARCH.CA) Stock Fundamental Analysis

TSX-V:ARCH - TSX Venture Exchange - CA03938C1041 - Common Stock - Currency: CAD

1.72  +0.01 (+0.58%)

Fundamental Rating

2

ARCH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 2 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of ARCH have multiple concerns. While showing a medium growth rate, ARCH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARCH had negative earnings in the past year.
ARCH had a negative operating cash flow in the past year.
In the past 5 years ARCH always reported negative net income.
ARCH had negative operating cash flow in 4 of the past 5 years.
ARCH.CA Yearly Net Income VS EBIT VS OCF VS FCFARCH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1M -2M -3M -4M

1.2 Ratios

ARCH has a Return On Assets (-551.08%) which is in line with its industry peers.
Industry RankSector Rank
ROA -551.08%
ROE N/A
ROIC N/A
ROA(3y)-309.85%
ROA(5y)-319.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARCH.CA Yearly ROA, ROE, ROICARCH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

ARCH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARCH.CA Yearly Profit, Operating, Gross MarginsARCH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

ARCH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ARCH has more shares outstanding
The debt/assets ratio for ARCH has been reduced compared to a year ago.
ARCH.CA Yearly Shares OutstandingARCH.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARCH.CA Yearly Total Debt VS Total AssetsARCH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

ARCH has an Altman-Z score of -85.87. This is a bad value and indicates that ARCH is not financially healthy and even has some risk of bankruptcy.
ARCH has a Altman-Z score (-85.87) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -85.87
ROIC/WACCN/A
WACCN/A
ARCH.CA Yearly LT Debt VS Equity VS FCFARCH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 0.13 indicates that ARCH may have some problems paying its short term obligations.
ARCH's Current ratio of 0.13 is in line compared to the rest of the industry. ARCH outperforms 50.00% of its industry peers.
ARCH has a Quick Ratio of 0.13. This is a bad value and indicates that ARCH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.13, ARCH is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
ARCH.CA Yearly Current Assets VS Current LiabilitesARCH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

6

3. Growth

3.1 Past

ARCH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.21%, which is quite impressive.
The Revenue for ARCH has decreased by -105.30% in the past year. This is quite bad
Measured over the past years, ARCH shows a very strong growth in Revenue. The Revenue has been growing by 86.56% on average per year.
EPS 1Y (TTM)47.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.09%
Revenue 1Y (TTM)-105.3%
Revenue growth 3Y-18.27%
Revenue growth 5Y86.56%
Sales Q2Q%-100%

3.2 Future

ARCH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.44% yearly.
The Revenue is expected to grow by 145.93% on average over the next years. This is a very strong growth
EPS Next Y0%
EPS Next 2Y-52.13%
EPS Next 3Y12.44%
EPS Next 5YN/A
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y145.93%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARCH.CA Yearly Revenue VS EstimatesARCH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2028 2029 2030 50M 100M 150M 200M 250M
ARCH.CA Yearly EPS VS EstimatesARCH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -0.05 -0.1 -0.15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ARCH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARCH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARCH.CA Price Earnings VS Forward Price EarningsARCH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARCH.CA Per share dataARCH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15

4.3 Compensation for Growth

ARCH's earnings are expected to grow with 12.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-52.13%
EPS Next 3Y12.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARCH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCH BIOPARTNERS INC

TSX-V:ARCH (7/11/2025, 7:00:00 PM)

1.72

+0.01 (+0.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)06-03 2025-06-03
Earnings (Next)08-27 2025-08-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners17.92%
Ins Owner ChangeN/A
Market Cap113.71M
Analysts45.71
Price Target3.57 (107.56%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -551.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-309.85%
ROA(5y)-319.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover-0.44
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z -85.87
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.09%
EPS Next Y0%
EPS Next 2Y-52.13%
EPS Next 3Y12.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-105.3%
Revenue growth 3Y-18.27%
Revenue growth 5Y86.56%
Sales Q2Q%-100%
Revenue Next Year0%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y145.93%
EBIT growth 1Y50.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.86%
EBIT Next 3Y-26.16%
EBIT Next 5Y82.56%
FCF growth 1Y-65.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.65%
OCF growth 3YN/A
OCF growth 5YN/A